Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182143 · ClinicalTrials.gov registry record · Phase 3
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
A Phase 3 study, sponsored by McMaster University.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,659
- Enrollment target
NCT00182143 is a Phase 3 study that has completed, run by McMaster University. The registered enrollment target is 3,659 participants.
The verdict
NCT00182143, a Phase 3 study, has completed, sponsored by McMaster University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,659 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
Interventions
- DRUG Unfractionated Heparin
- DRUG LMWH (Fragmin, dalteparin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,659 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00182143
The ClinicalTrials.gov registry entry for NCT00182143 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,659 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McMaster University, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unfractionated Heparin is the first listed.
NCT00182143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00182143 about?
NCT00182143 is a clinical study titled "PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)". The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism...
What is the current status of trial NCT00182143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,659 participants. The study started on 2006-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00182143?
The interventions under investigation include: Unfractionated Heparin (DRUG), LMWH (Fragmin, dalteparin) (DRUG).
Who is sponsoring clinical trial NCT00182143?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.